top of page
  • Recruiting

NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Updated: Sep 16, 2022

Talquetamab Phase 1b study

Phase 1 - Talquetamab in Multiple Myeloma

NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.



Multiple locations

International Study Identifier: NCT05050097

Official Title: A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted : September 20, 2021

Click here to see details on


Treatment Regimen A: Talquetamab + Carfilzomib

Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib

Treatment Regimen C: Talquetamab + Lenalidomide

Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide

Treatment Regimen E: Talquetamab + Pomalidomide


Drug: Talquetamab (SC)

bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D)

JNJ 64407564


Drug: Carfilzomib ( Kyprolis)

Drug: Daratumumab SC ( DARZALEX FASPRO)

Drug: Lenalidomide (Revlimid)

Drug: Pomalidomide (Pomalyst)


- Multiple locations

- International study


- Alabama: University of Alabama at Birmingham

- California: University of California San Francisco

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Georgia: Emory University Atlanta

- Indiana: Indiana University Indianapolis

- New Jersey: Hackensack University Medical Center

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- North Carolina: Levine Cancer Institute Charlotte

- Pennsylvania: University of Pittsburgh Medical Center

- Tennessee: Sarah Cannon Research Institute Nashville

- Wisconsin: Medical College Of Wisconsin Milwaukee



United States, Alabama

United States, California

United States, Colorado

United States, Georgia

United States, Indiana

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Tennessee

United States, Wisconsin


United Kingdom








NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

CT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)



NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma



NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2


Posts Archive
bottom of page